GC
KURA icon

Guggenheim Capital’s Kura Oncology KURA Stock Holding History

Guggenheim Capital’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,670
Closed -$119K – 1743
2026
Q1 		$119K Buy
+14,670
New +$126K ﹤0.01% 1566
2022
Q4 		– Sell
-21,770
Closed -$297K – 1952
2022
Q3 		$297K Sell
21,770
-1,200
-5% -$18.5K ﹤0.01% 1661
2022
Q2 		$421K Sell
22,970
-1,701
-7% -$24.5K ﹤0.01% 1646
2022
Q1 		$397K Buy
24,671
+914
+4% +$13.2K ﹤0.01% 1765
2021
Q4 		$333K Buy
23,757
+348
+1% +$5.64K ﹤0.01% 1829
2021
Q3 		$438K Sell
23,409
-543
-2% -$10.2K ﹤0.01% 1796
2021
Q2 		$499K Buy
23,952
+1,096
+5% +$27.2K ﹤0.01% 1829
2021
Q1 		$646K Buy
22,856
+10,900
+91% +$345K ﹤0.01% 1598
2020
Q4 		$390K Buy
+11,956
New +$420K ﹤0.01% 1740

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Guggenheim Capital's KURA Position: Q2 2026 in Review

Guggenheim Capital sold out of Kura Oncology (KURA) in Q2 2026, closing a stake of 14,670 shares — an estimated $119K sold.

Guggenheim Capital first reported a position in KURA in Q4 2020 and held it in 9 quarters. The position peaked at $646K in Q1 2021. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Guggenheim Capital reported no remaining Kura Oncology position as of Q2 2026 after selling out during the quarter.
  • Guggenheim Capital sold 14,670 Kura Oncology shares in Q2 2026, an estimated $119K.
  • Guggenheim Capital first reported a position in Kura Oncology in Q4 2020 and held it in 9 quarters.
  • Guggenheim Capital's Kura Oncology position peaked at $646K in Q1 2021.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.